Loven David, Hardoff Ruth, Sever Zvi Bar, Steinmetz Adam P, Gornish Michael, Rappaport Zvi H, Fenig Eyal, Ram Zvi, Sulkes Aaron
Institute of Oncology, Ha'Emek Medical Center, Afula, Israel.
J Neurooncol. 2004 Mar-Apr;67(1-2):221-6. doi: 10.1023/b:neon.0000021827.85754.8e.
To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas.
Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day. Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT. One minimal response was documented by CT, accompanied by clinical stabilization. Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24). Two other patients were not available for response due to early removal from the study, following abrupt manifestation of grades 3-4 hematological toxicity.
In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.
测试羟基脲在治疗复发性和不可切除的生长缓慢的脑膜瘤中的疗效。
12例非恶性脑膜瘤复发患者参加了一项为期2年的方案,持续使用羟基脲化疗,剂量为20mg/kg/天。通过临床评估以及使用计算机断层扫描(CT)和铊-201单光子发射CT进行诊断成像来评估治疗反应。CT记录到1例最小反应,伴有临床病情稳定。9例患者至少通过一种成像检查显示疾病进展,进展的中位时间为13个月(范围4-24个月)。另外2例患者因在出现3-4级血液学毒性后被提前退出研究而无法评估反应。
在本系列研究中,羟基脲在治疗不可切除的生长缓慢的脑膜瘤方面未显示出有效性:既未实现反应,也未阻止疾病进展。